CelularityvsMerck & Company

CELU and MRK stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$146.51

Value $362B

-0.84%
MRK's page

Celularity (CELU) has a market value of $19M and Merck & Company (MRK) $362B. Over the last year, with dividends, CELU moved -61.3% and MRK +62.3%. Dividend yield: CELU none, MRK 2.32%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CELU$19M

    MRK$362B

    MRK is 18,605 times CELU

  • Revenue, 12 months

    CELU$19M

    MRK$67.4B

    MRK is 3,610 times CELU

  • Net income, 12 months

    CELU-$46M

    MRK$2.5B

  • Operating margin

    CELU-264.3%

    MRK–

  • ROIC

    CELU–

    MRK3.9%

  • P/E

    CELU–

    MRK147.7

  • Dividend yield

    CELU0.0%

    MRK2.3%

    2.3 points apart

  • 5-year return

    CELU-99.1%

    MRK+103.9%

    203.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CELU-99.1%

MRK+103.9%

010020020222023202420252026
Returns by period
PeriodCELUWith dividendsMRKWith dividends
1 year since November 14, 2025-61.3%Price -61.3%+62.3%Price +57.7%
3 years since November 16, 2023-70.0%-33.1% a yearPrice -70.0%+57.4%+16.3% a yearPrice +43.7%
5 years since November 15, 2021-99.1%-61.2% a yearPrice -99.1%+103.9%+15.3% a yearPrice +75.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CELUCelularityMRKMerck & Company

Valuation

CELUMRK
Valuation
Price$0.60$146.51
Market value$19M$362B
Enterprise value (EV)$43M$406B
P/E–147.7
P/E, 5-year median–14.8
P/B–8.1
EV/EBIT–85.3
Free cash flow yield–4.1%

Results and growth

CELUMRK
Results and growth
Revenue, 12 months$19M$67.4B
Net income, 12 months-$46M$2.5B
Free cash flow, 12 months–$14.7B
Earnings per share, 12 months-$1.69$0.98
Revenue growth, year on year-51.0%1.3%
Revenue growth a year, past+13.2%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

CELUMRK
Margins and returns on capital
Gross margin19.2%71.8%
Operating margin-264.3%–
Net margin-245.7%3.6%
ROIC–3.9%
ROE–5.2%

Balance sheet

CELUMRK
Balance sheet
Cash$10M$9.7B
Total debt$61M$53.8B
Net debt / EBITDA–5.7
Interest cover-5,480.9×2.4×

Dividends and buybacks

CELUMRK
Dividends and buybacks
Dividend yield–2.3%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CELU or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Celularity or Merck & Company?

By market value, Merck & Company ($362B) is about 18,604.8 times Celularity ($19M), at today's prices.

How did CELU and MRK stock do over the last 5 years?

Since November 15, 2021, CELU's price moved -99.1% and MRK's +75.1%. With dividends: CELU -99.1% (-61.2% a year), MRK +103.9% (+15.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, CELU or MRK?

The dividend yield at today's price is none for Celularity and 2.32% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Celularity or Merck & Company?

Over the last twelve months, the net margin was -245.7% for Celularity and 3.6% for Merck & Company, and the operating margin -264.3% and –. Revenue was $19M and $67.4B.

Which is the better investment, Celularity or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.